Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2025-03-27 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于回购注销部分限制性股票减资暨通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the repurchase and cancellation of some restricted shares, which leads to a reduction in registered capital. It includes a notification to creditors about their rights to claim debts or request guarantees within 45 days. The content focuses on the company's share repurchase and capital reduction, with procedural details for creditors. There is no financial report, earnings data, or management discussion. The document is a formal announcement about a share repurchase and capital change event, not a full report or financial statement. Therefore, it fits best under the category of Transaction in Own Shares (POS). The document length is short and it is not a report publication announcement or certification. Hence, the classification is POS with high confidence.
2025-03-27 Chinese
独立董事2024年度述职报告（耿小平）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Anhui Anke Biotechnology (Group) Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, participation in committees, communication with auditors, and engagement with shareholders during the 2024 fiscal year. The content is a narrative report on the director's duties and oversight rather than financial statements or audit results. It is not an announcement of voting results, management changes, or legal proceedings. The document is a formal report by an independent director on their annual duties and oversight, which fits best under Board/Management Information (MANG) as it relates to governance and management oversight activities. The document length is 2643 characters, which is relatively short but contains substantive content about management oversight rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-03-27 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to the "2024 Supervisory Board Work Report". It details the supervisory board's activities, oversight of company operations, financial supervision, internal control evaluations, and opinions on profit distribution and related party transactions for the year 2024. The content is a formal report from the supervisory board summarizing their work and findings for the year, which is typical of a management or supervisory report rather than a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on governance and oversight activities. This fits best under the category of Management Reports (MDA), which include management's detailed explanations of financial results, business trends, and outlook, as well as supervisory board reports on company operations and governance.
2025-03-27 Chinese
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the progress of implementing the 'Quality and Return Double Improvement' action plan. It discusses operational updates, R&D progress, clinical trials, dividend distribution plans, and governance improvements. The document includes details about dividend proposals and shareholder returns but does not contain full financial statements or comprehensive financial data. It is a progress update and corporate announcement rather than a full annual or interim report. The document length is 3331 characters, which is relatively short and more consistent with an announcement rather than a full report. It also includes dividend distribution information, but since it is part of a broader progress update and not solely a dividend notice, it is not classified as a Notice of Dividend Amount (DIV). The document does not fit the criteria for Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or other detailed financial reports. It is best classified as a Regulatory Filing (RNS) because it is a general corporate announcement about progress, governance, and shareholder returns without full financial statements or detailed financial analysis.
2025-03-27 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biological Engineering (Group) Co., Ltd. regarding the company's plan to apply for a comprehensive credit line from banks. It details the board meeting resolution, the amount of credit requested, authorization for the chairman to sign related documents, and the need for shareholder approval. The content focuses on financing activities and capital structure changes, specifically about bank credit facilities. The document length is short (604 characters) and is an announcement, not a detailed financial report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-03-27 Chinese
董事会决议公告
AGM Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 8th Board of Directors of Anhui Anke Biological Engineering (Group) Co., Ltd. It includes approvals of various reports such as the 2024 President's Work Report, 2024 Board Work Report, 2024 Financial Final Report, 2024 Annual Report and its summary, profit distribution plan, internal control self-evaluation report, and other corporate governance matters. The document also mentions that these reports and detailed contents are published on the official disclosure website (cninfo.com.cn) and will be submitted to the 2024 Annual General Meeting for approval. The document is not the reports themselves but an announcement of the board meeting decisions and the intention to submit these reports to the shareholders' meeting. It contains voting results and procedural details of the board meeting. This fits the category of AGM Information (AGM-R), as it is the materials and resolutions shared during the Annual General Meeting process, including the board meeting leading up to it. The document is over 7,000 characters, so it is not a mere brief announcement but a full disclosure of board meeting resolutions related to the AGM.
2025-03-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.